middle.news
How Zelira Therapeutics Slashed Losses While Advancing HOPE® FDA Trials
4:27am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Zelira Therapeutics Slashed Losses While Advancing HOPE® FDA Trials
4:27am on Saturday 30th of August, 2025 AEST
Key Points
FY25 loss narrowed 90% to AUD 3.85 million
Revenue declined sharply to AUD 656 amid clinical focus
HOPE® 1 FDA trial preparations advanced via SPV with US$3.25M convertible notes converted to equity
New patents granted for autism spectrum disorder formulations in Australia and US
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE